News
MarketBeat on MSN12d
Will Hims & Hers Fall Along With Novo Nordisk?
One of the most widely watched names in the healthcare sector is Hims & Hers Health Inc. (NYSE: HIMS), not only due to its ...
Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...
Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...
4don MSN
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...
Despite the setback with HIMS, CVS Caremark, a major pharmacy benefit manager, had announced that it would make Novo Nordisk’s Wegovy its preferred GLP-1 therapy for weight loss, effective July ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy.
Danish leader will face a challenging landscape among competitors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback